Search
Searching Content indexed under Intellectual Property by Joanne Hawana ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Counterfeit Products Are Often Unsafe Products – More Reasons To Aggressively Police Infringement Of Your Trademarks And Trade Dress
Our colleagues in Mintz Levin's Intellectual Property Practice, recently authored an expert analysis piece in Law360 that examined the use of the U.S. ITC to combat a rising tide of counterfeits...
United States
3 Nov 2016
2
6-Month Notice From A Biosimilar Sponsor Always Required — Says Federal Circuit
The court stated clearly that the answer to that question is "No" and that notice of commercial marketing is always required after FDA's date of licensure for the biosimilar.
United States
8 Jul 2016
3
Positive FDA Advisory Committee Vote For First Monoclonal Antibody Biosimilar – But Will Patent Dispute Delay Launch?
Tuesday, February 9th was a busy day for Korean biologics company Celltrion Inc. The company had its proposed biosimilar CT-P13 before the FDA Arthritis Advisory Committee as well as a hearing in federal court in Massachusetts.
United States
12 Feb 2016
4
First Monoclonal Antibody Biosimilar In U.S. Gets One Step Closer To FDA Approval
Yesterday, the FDA's Arthritis Advisory Committee voted 21-3 to recommend that CT-P13, Celltrion's proposed biosimilar of Janssen Biotech, Inc.'s Remicade® (infliximab) be approved for all indications.
United States
11 Feb 2016
Links to Result pages
 
1